PAP
GPCR icon

Persistent Asset Partners’s Structure Therapeutics GPCR Stock Holding History

Persistent Asset Partners’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-323
Closed -$42.6K – 853
2026
Q1 		$42.6K Buy
+323
New +$22.1K 0.02% 264

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Persistent Asset Partners's GPCR Position: Q2 2026 in Review

Persistent Asset Partners sold out of Structure Therapeutics (GPCR) in Q2 2026, closing a stake of 18,263 shares — an estimated $880K sold.

Persistent Asset Partners first reported a position in GPCR in Q4 2025 and held it in 2 quarters. The position peaked at $880K in Q1 2026. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Persistent Asset Partners reported no remaining Structure Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 18,263 Structure Therapeutics shares in Q2 2026, an estimated $880K.
  • Persistent Asset Partners first reported a position in Structure Therapeutics in Q4 2025 and held it in 2 quarters.
  • Persistent Asset Partners's Structure Therapeutics position peaked at $880K in Q1 2026.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.